Zamarin et al. showed that localized oncolytic NDV in combination with systemic anti-CTLA-4 blockade can eradicate tumors in B16 melanoma by producing curative immune responses that require CD8+ T cells, NK cells, and type I IFNs [102]. The gene discussed is CD8A; the disease is melanoma.